Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis

Surgical Oncology - Tập 26 - Trang 125-137 - 2017
Amir A. Rahnemai-Azar1, Allison Weisbrod2, Mary Dillhoff2, Carl Schmidt2, Timothy M. Pawlik2
1Department of Surgery, University of Washington Medical Center, Seattle, WA, USA
2Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA

Tài liệu tham khảo

Global Burden of Disease Cancer C, 2015, The Global Burden of Cancer 2013, JAMA Oncol, 1, 505, 10.1001/jamaoncol.2015.0735

Aljiffry, 2009, Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature, J. Am. Coll. Surg., 208, 134, 10.1016/j.jamcollsurg.2008.09.007

Razumilava, 2014, Cholangiocarcinoma, Lancet, 383, 2168, 10.1016/S0140-6736(13)61903-0

Shaib, 2004, Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?, J. Hepatol., 40, 472, 10.1016/j.jhep.2003.11.030

Patel, 2001, Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States, Hepatology, 33, 1353, 10.1053/jhep.2001.25087

Blechacz, 2011, Clinical diagnosis and staging of cholangiocarcinoma, Nat. Rev. Gastroenterol. Hepatol., 8, 512, 10.1038/nrgastro.2011.131

Weber, 2015, Intrahepatic cholangiocarcinoma: expert consensus statement, HPB (Oxford), 17, 669, 10.1111/hpb.12441

Banales, 2016, Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA), Nat. Rev. Gastroenterol. Hepatol., 13, 261, 10.1038/nrgastro.2016.51

Nathan, 2007, Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis, J. Gastrointest. Surg., 11, 1488, 10.1007/s11605-007-0282-0

Bekaii-Saab, 2011, Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers, J. Clin. Oncol., 29, 2357, 10.1200/JCO.2010.33.9473

Costello, 2014, Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors, Investig. New Drugs, 32, 710, 10.1007/s10637-014-0096-3

Borad, 2014, Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma, PLoS Genet., 10, e1004135, 10.1371/journal.pgen.1004135

Sia, 2013, Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies, Oncogene, 32, 4861, 10.1038/onc.2012.617

Andersen, 2015, Molecular pathogenesis of intrahepatic cholangiocarcinoma, J. Hepatobiliary Pancreatic Sci., 22, 101, 10.1002/jhbp.155

Bridgewater, 2014, Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma, J. Hepatol., 60, 1268, 10.1016/j.jhep.2014.01.021

Berthiaume, 2004, The molecular pathogenesis of cholangiocarcinoma, Semin. Liver Dis., 24, 127, 10.1055/s-2004-828890

Komuta, 2012, Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes, Hepatology, 55, 1876, 10.1002/hep.25595

Roskams, 2006, Liver stem cells and their implication in hepatocellular and cholangiocarcinoma, Oncogene, 25, 3818, 10.1038/sj.onc.1209558

Sirica, 2008, Pathobiology of biliary epithelia and cholangiocarcinoma: proceedings of the Henry M. and Lillian Stratton basic research single-topic conference, Hepatolgy, 48, 2040, 10.1002/hep.22623

McKay, 2011, Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma, HPB (Oxford), 13, 309, 10.1111/j.1477-2574.2010.00286.x

Homayounfar, 2009, Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization, Hum. Pathol., 40, 834, 10.1016/j.humpath.2008.11.005

Yoshida, 1995, Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers, Cancer Res., 55, 2756

Dachrut, 2009, DNA copy-number loss on 1p36.1 harboring RUNX3 with promoter hypermethylation and associated loss of RUNX3 expression in liver fluke-associated intrahepatic cholangiocarcinoma, Asian Pac. J. Cancer Prev., 10, 575

Huang, 2016, Screening of potential biomarkers for cholangiocarcinoma by integrated analysis of microarray data sets, Cancer Gene Ther., 23, 48, 10.1038/cgt.2015.66

Seol, 2011, Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentiation of cholangiocarcinoma, BMC Cancer, 11, 78, 10.1186/1471-2407-11-78

Li, 2013, Gene expression patterns combined with bioinformatics analysis identify genes associated with cholangiocarcinoma, Comput. Biol. Chem., 47, 192, 10.1016/j.compbiolchem.2013.08.010

Subrungruanga, 2013, Gene expression profiling of intrahepatic cholangiocarcinoma, Asian Pac. J. Cancer Prev., 14, 557, 10.7314/APJCP.2013.14.1.557

Wu, 2011, Candidate genes involving in tumorigenesis of cholangiocarcinoma induced by Opisthorchis viverrini infection, Parasitol. Res., 109, 657, 10.1007/s00436-011-2298-3

Xu, 2011, KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients, Biomed. Pharmacother., 65, 22, 10.1016/j.biopha.2010.06.009

Isa, 2002, Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma, Hepatogastroenterology, 49, 604

Xie, 2016, Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy, Am. J. Cancer Res., 6, 577

Menakongka, 2010, Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion, World J. Gastroenterol., 16, 713, 10.3748/wjg.v16.i6.713

Chen, 2014, Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma, Oncotarget, 5, 2372, 10.18632/oncotarget.1706

Herberger, 2007, Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma, Clin. Cancer Res., 13, 4795, 10.1158/1078-0432.CCR-07-0738

Singh, 2011, The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma, Dig. Dis. Sci., 56, 2491, 10.1007/s10620-011-1709-8

Leelawat, 2010, Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma, World J. Gastroenterol., 16, 4697, 10.3748/wjg.v16.i37.4697

Patel, 2000, The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis, Am. J. Gastroenterol., 95, 204, 10.1111/j.1572-0241.2000.01685.x

Charatcharoenwitthaya, 2008, Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis, Hepatology, 48, 1106, 10.1002/hep.22441

Qin, 2004, Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA, World J. Gastroenterol., 10, 427, 10.3748/wjg.v10.i3.427

Nehls, 2004, Serum and bile markers for cholangiocarcinoma, Semin. Liver Dis., 24, 139, 10.1055/s-2004-828891

Viterbo, 2016, Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy, World J. Gastrointest. Endosc., 8, 128, 10.4253/wjge.v8.i3.128

Morris-Stiff, 2009, CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease, Hepatobiliary Pancreat. Dis. Int., 8, 620

Levy, 2005, The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis, Dig. Dis. Sci., 50, 1734, 10.1007/s10620-005-2927-8

Ramage, 1995, Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis, Gastroenterology, 108, 865, 10.1016/0016-5085(95)90462-X

Liang, 2015, Diagnostic accuracy of serum CA19-9 in patients with cholangiocarcinoma: a systematic review and meta-analysis, Med. Sci. Monit., 21, 3555, 10.12659/MSM.895040

Shen, 2009, Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma, World J. Gastroenterol., 15, 5976, 10.3748/wjg.15.5976

Liu, 2010, Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: a meta-analysis, Front. Med. China, 4, 457, 10.1007/s11684-010-0240-1

Kobayashi, 2005, Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells, Gastroenterology, 128, 2054, 10.1053/j.gastro.2005.03.010

Neurath, 2011, IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer, Cytokine Growth Factor Rev., 22, 83, 10.1016/j.cytogfr.2011.02.003

Sansone, 2012, Targeting the interleukin-6/Jak/stat pathway in human malignancies, J. Clin. Oncol., 30, 1005, 10.1200/JCO.2010.31.8907

Sia, 2013, Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes, Gastroenterology, 144, 829, 10.1053/j.gastro.2013.01.001

Cheon, 2007, Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy, Am. J. Gastroenterol., 102, 2164, 10.1111/j.1572-0241.2007.01403.x

Goydos, 1998, Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker, Ann. Surg., 227, 398, 10.1097/00000658-199803000-00012

Bonney, 2008, Circulating markers of biliary malignancy: opportunities in proteomics?, Lancet. Oncol., 9, 149, 10.1016/S1470-2045(08)70027-5

Xu, 2008, Elevation of serum KL-6 mucin levels in patients with cholangiocarcinoma, Hepatogastroenterology, 55, 2000

Matull, 2008, MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer, Br. J. Cancer, 98, 1675, 10.1038/sj.bjc.6604364

Sawanyawisuth, 2012, A novel carbohydrate antigen expression during development of Opisthorchis viverrini- associated cholangiocarcinoma in golden hamster: a potential marker for early diagnosis, Parasitol. Int., 61, 151, 10.1016/j.parint.2011.07.013

Silsirivanit, 2011, A novel serum carbohydrate marker on mucin 5AC: values for diagnostic and prognostic indicators for cholangiocarcinoma, Cancer, 117, 3393, 10.1002/cncr.25912

Wu, 2012, The clinicopathological and prognostic impact of 14-3-3 protein isoforms expression in human cholangiocarcinoma by immunohistochemistry, Asian Pac. J. Cancer Prev., 13, 1253, 10.7314/APJCP.2012.13.4.1253

Zhang, 2015, Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications, Tumour Biol., 36, 1781, 10.1007/s13277-014-2780-5

Khongmanee, 2013, Proteomic analysis reveals important role of 14-3-3sigma in anoikis resistance of cholangiocarcinoma cells, Proteomics, 13, 3157, 10.1002/pmic.201300219

Eigenbrodt, 1998, Pyruvate kinase and the interaction of amino acid and carbohydrate metabolism in solid tumors, Anticancer Res., 18, 3267

Li, 2009, Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma, Dig. Liver Dis., 41, 605, 10.1016/j.dld.2008.11.010

Suzuki, 2015, Relationship between 18-F-fluoro-deoxy-D-glucose uptake and expression of glucose transporter 1 and pyruvate kinase M2 in intrahepatic cholangiocarcinoma, Dig. Liver Dis., 47, 590, 10.1016/j.dld.2015.03.017

Lesurtel, 2006, Platelet-derived serotonin mediates liver regeneration, Science, 312, 104, 10.1126/science.1123842

Alpini, 2008, Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth, Cancer Res., 68, 9184, 10.1158/0008-5472.CAN-08-2133

Takada, 1995, Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay, Br. J. Cancer, 71, 160, 10.1038/bjc.1995.33

Nakata, 2004, Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer, Br. J. Cancer, 91, 873, 10.1038/sj.bjc.6602074

Nakata, 1996, Clinical significance of serum CYFRA 21-1 in gastric cancer, Br. J. Cancer, 73, 1529, 10.1038/bjc.1996.288

Lumachi, 2014, Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study, Anticancer Res., 34, 6663

Chapman, 2011, Circulating CYFRA 21-1 is a specific diagnostic and prognostic biomarker in biliary tract cancer, J. Clin. Exp. Hepatol., 1, 6, 10.1016/S0973-6883(11)60110-2

Uenishi, 2008, Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma, Ann. Surg. Oncol., 15, 583, 10.1245/s10434-007-9650-y

Kashihara, 1998, Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level, J. Gastroenterol., 33, 447, 10.1007/s005350050112

Tao, 2010, Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma, Am. Surg., 76, 1210, 10.1177/000313481007601119

Van Eyken, 1993, Cytokeratins and the liver, Liver, 13, 113, 10.1111/j.1600-0676.1993.tb00617.x

Janvilisri, 2015, Novel serum biomarkers to differentiate cholangiocarcinoma from benign biliary tract diseases using a proteomic approach, Dis. Markers, 2015, 105358, 10.1155/2015/105358

Shi, 2013, High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery, Cancer, 119, 993, 10.1002/cncr.27788

Tolek, 2012, Serum alpha1beta-glycoprotein and afamin ratio as potential diagnostic and prognostic markers in cholangiocarcinoma, Exp. Biol. Med. (Maywood), 237, 1142, 10.1258/ebm.2012.012215

Li, 2015, Application of joint detection of AFP, CA19-9, CA125 and CEA in identification and diagnosis of cholangiocarcinoma, Asian Pac. J. Cancer Prev., 16, 3451, 10.7314/APJCP.2015.16.8.3451

Miwa, 2006, Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery, J. Gastroenterol., 41, 893, 10.1007/s00535-006-1877-z

Siqueira, 2002, Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis, Gastrointest. Endosc., 56, 40, 10.1067/mge.2002.125105

Berbec, 1999, Total serum sialic acid concentration as a supporting marker of malignancy in ovarian neoplasia, Eur. J. Gynaecol. Oncol., 20, 389

Narayanan, 1994, Sialic acid as a tumor marker, Ann. Clin. Lab. Sci., 24, 376

Wongkham, 2001, Serum total sialic acid in cholangiocarcinoma patients: an ROC curve analysis, Clin. Biochem., 34, 537, 10.1016/S0009-9120(01)00265-X

Kongtawelert, 2003, Role of serum total sialic acid in differentiating cholangiocarcinoma from hepatocellular carcinoma, World J. Gastroenterol., 9, 2178, 10.3748/wjg.v9.i10.2178

Matsuda, 2010, Wisteria floribunda agglutinin-positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma, Hepatology, 52, 174, 10.1002/hep.23654

Shi, 2013, A prospective proteomic-based study for identifying potential biomarkers for the diagnosis of cholangiocarcinoma, J. Gastrointest. Surg., 17, 1584, 10.1007/s11605-013-2182-9

Wang, 2009, Characterization of apolipoprotein A-I as a potential biomarker for cholangiocarcinoma, Eur. J. Cancer Care (Engl.), 18, 625, 10.1111/j.1365-2354.2008.00965.x

Dos Santos, 2010, Identification of cellular targets in human intrahepatic cholangiocarcinoma using laser microdissection and accurate mass and time tag proteomics, Mol. Cell. Proteom., 9, 1991, 10.1074/mcp.M110.000026

Liu, 2008, Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma, J. Cell. Biochem., 104, 745, 10.1002/jcb.21661

Park, 2006, Bile acid analysis in biliary tract cancer, Yonsei Med. J., 47, 817, 10.3349/ymj.2006.47.6.817

Nagana Gowda, 2009, Visualization of bile homeostasis using (1)H-NMR spectroscopy as a route for assessing liver cancer, Lipids, 44, 27, 10.1007/s11745-008-3254-6

Farina, 2009, Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer, J. Proteome Res., 8, 159, 10.1021/pr8004925

Albiin, 2008, Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis, Acta Radiol., 49, 855, 10.1080/02841850802220092

Shen, 2012, Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma, PLoS One, 7, e47476, 10.1371/journal.pone.0047476

Sato, 2013, Clinicopathological significance of S100 protein expression in cholangiocarcinoma, J. Gastroenterol. Hepatol., 28, 1422, 10.1111/jgh.12247

Koopmann, 2004, Case 7-2004: hereditary melanoma and pancreatic cancer, N. Engl. J. Med., 350, 2623, 10.1056/NEJM200406173502521

Metzger, 2013, Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders, Gut, 62, 122, 10.1136/gutjnl-2012-302047

Chen, 2015, TGF-β1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma, Biol. Res., 48, 26, 10.1186/s40659-015-0016-9

Yan, 2013, Inactivation of Smad4 is a prognostic factor in intrahepatic cholangiocarcinoma, Chin. Med. J. (Engl.), 126, 3039

Zhang, 2005, Expression of Smad4 and transforming growth factor-beta1, transforming growth factor-beta receptor II in cholangiocarcinoma tissue and its biological significance, Zhonghua Wai Ke Za Zhi (Chin. J. Surg.), 43, 846

Chuang, 2004, Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers, World J. Surg., 28, 995, 10.1007/s00268-004-7447-8

Sato, 2010, Epithelial-mesenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangiocarcinoma, Am. J. Pathol., 177, 141, 10.2353/ajpath.2010.090747

Terada, 1998, Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis, Hum. Pathol., 29, 175, 10.1016/S0046-8177(98)90229-5

Miyamoto, 2011, Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma, Br. J. Cancer, 105, 131, 10.1038/bjc.2011.199

Itatsu, 2008, Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts, Hum. Pathol., 39, 710, 10.1016/j.humpath.2007.09.016

Miwa, 2002, Matrix metalloproteinase-7 expression and biologic aggressiveness of cholangiocellular carcinoma, Cancer, 94, 428, 10.1002/cncr.10235

Yoshikawa, 2008, Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma, Br. J. Cancer, 98, 418, 10.1038/sj.bjc.6604129

Park, 2006, The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma, Am. J. Clin. Oncol., 29, 138, 10.1097/01.coc.0000204402.29830.08

Korita, 2010, Aberrant expression of vimentin correlates with dedifferentiation and poor prognosis in patients with intrahepatic cholangiocarcinoma, Anticancer Res., 30, 2279

Sirica, 2008, Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma, World J. Gastroenterol., 14, 7033, 10.3748/wjg.14.7033

Hoffmann, 2013, EGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma, PloS One, 8, e64186, 10.1371/journal.pone.0064186

Tannapfel, 2000, Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver, Dig. Dis. Sci., 45, 317, 10.1023/A:1005412626515

Kirsch, 1998, Tumor-suppressor p53: implications for tumor development and prognosis, J. Clin. Oncol., 16, 3158, 10.1200/JCO.1998.16.9.3158

Chen, 2012, K-ras mutation is strongly associated with perineural invasion and represents an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy, Ann. Surg. Oncol., S675, 10.1245/s10434-012-2224-7

Wang, 2013, Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas, Oncogene, 32, 3091, 10.1038/onc.2012.315

Kipp, 2012, Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma, Hum. Pathol., 43, 1552, 10.1016/j.humpath.2011.12.007

Tannapfel, 2002, Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma, J. Pathol., 197, 624, 10.1002/path.1139

Tannapfel, 2000, Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver, Gut, 47, 721, 10.1136/gut.47.5.721

Wong, 2002, Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma, J. Hepatol., 37, 633, 10.1016/S0168-8278(02)00269-6

Chen, 2009, The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma, J. Hepatol., 50, 358, 10.1016/j.jhep.2008.09.015

Oishi, 2012, Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma, Hepatology, 56, 1792, 10.1002/hep.25890

Silakit, 2014, Circulating miR-192 in liver fluke-associated cholangiocarcinoma patients: a prospective prognostic indicator, J. Hepatobiliary Pancreat. Sci., 21, 864, 10.1002/jhbp.145

Plieskatt, 2014, Distinct miRNA signatures associate with subtypes of cholangiocarcinoma from infection with the tumourigenic liver fluke Opisthorchis viverrini, J. Hepatol., 61, 850, 10.1016/j.jhep.2014.05.035

Li, 2014, Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis, Hepatology, 60, 896, 10.1002/hep.27050

Verma, 1994, Carcinoma associated mucins: molecular biology and clinical applications, Cancer Biochem. Biophys., 14, 151

Sasaki, 1996, Characterization of apomucin expression in intrahepatic cholangiocarcinomas and their precursor lesions: an immunohistochemical study, Hepatology, 24, 1074, 10.1002/hep.510240516

Matsumura, 2002, Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma, Cancer, 94, 1770, 10.1002/cncr.10398

Boonla, 2005, MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma, World J. Gastroenterol., 11, 4939, 10.3748/wjg.v11.i32.4939

Lang, 2007, Gel-forming mucins appeared early in metazoan evolution, Proc. Natl. Acad. Sci. U. S. A., 104, 16209, 10.1073/pnas.0705984104

Higashi, 1999, Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma, Hepatology, 30, 1347, 10.1002/hep.510300609

Shibahara, 2004, MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type, Hepatology, 39, 220, 10.1002/hep.20031

Chen, 2002, The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma-the influence of sampling time and hepatolithiasis, Hepato-gastroenterology, 49, 616

Higashi, 2012, Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type, Pathobiology, 79, 101, 10.1159/000335164

McCawley, 2000, Matrix metalloproteinases: multifunctional contributors to tumor progression, Mol. Med. Today, 6, 149, 10.1016/S1357-4310(00)01686-5

Mosig, 2007, Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth, Hum. Mol. Genet., 16, 1113, 10.1093/hmg/ddm060

Bao, 2010, HER2-mediated upregulation of MMP-1 is involved in gastric cancer cell invasion, Arch. Biochem. Biophys., 499, 49, 10.1016/j.abb.2010.05.009

Prakobwong, 2012, Plasma hydroxyproline, MMP-7 and collagen I as novel predictive risk markers of hepatobiliary disease-associated cholangiocarcinoma, Int. J. Cancer, 131, E416, 10.1002/ijc.26443

Shirabe, 1999, Expression of matrix metalloproteinase-9 in surgically resected intrahepatic cholangiocarcinoma, Surgery, 126, 842, 10.1016/S0039-6060(99)70024-3

Kirimlioglu, 2009, Turk J. Gastroenterol., 20, 41

Gardini, 2005, Expression of connective tissue growth factor is a prognostic marker for patients with intrahepatic cholangiocarcinoma, Dig. Liver Dis., 37, 269, 10.1016/j.dld.2004.11.001

Tanaka, 2003, Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma, Hepatology, 37, 1122, 10.1053/jhep.2003.50187

Thanan, 2012, Inflammation-induced protein carbonylation contributes to poor prognosis for cholangiocarcinoma, Free Radic. Biol. Med., 52, 1465, 10.1016/j.freeradbiomed.2012.01.018

Shirota, 2015, Heat shock protein 90 is a potential therapeutic target in cholangiocarcinoma, Mol. Cancer Ther., 14, 1985, 10.1158/1535-7163.MCT-15-0069

Nam, 2015, Preoperative C-reactive protein as a prognostic factor for recurrence after surgical resection of biliary tract cancer, Korean J. Clin. Oncol., 11, 101, 10.14216/kjco.15017

Saisho, 2005, Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy, Hepatogastroenterology, 52, 1654

Yonglitthipagon, 2012, Proteomics-based identification of alpha-enolase as a potential prognostic marker in cholangiocarcinoma, Clin. Biochem., 45, 827, 10.1016/j.clinbiochem.2012.04.004

Yonglitthipagon, 2012, Prognostic significance of peroxiredoxin 1 and ezrin-radixin-moesin-binding phosphoprotein 50 in cholangiocarcinoma, Hum. Pathol., 43, 1719, 10.1016/j.humpath.2011.11.021

Yin, 2013, Elevation of serum gamma-glutamyltransferase as a predictor of aggressive tumor behaviors and unfavorable prognosis in patients with intrahepatic cholangiocarcinoma: analysis of a large monocenter study, Eur. J. Gastroenterol. Hepatol., 25, 1408, 10.1097/MEG.0b013e328364130f

Batmunkh, 2007, Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma, Hum. Pathol., 38, 1508, 10.1016/j.humpath.2007.02.017

Thông tin
Thông tin xuất bản

Surgical Oncology

Tập 26

125-137

Thông tin tác giả